---
source: https://www.businesswire.com/news/home/20251110450301/en/Quanterix-Releases-Financial-Results-for-the-Third-Quarter-of-2025
date: 2025-11-10
type: Company
---

# Quanterix Q3 2025 Financial Results

Quanterix reported Q3 2025 results showing 12% YoY revenue growth.

## Financial Highlights

- **Revenue:** $40.2M (12% YoY increase from $35.8M)
- **GAAP Gross Margin:** 42.8% (vs 56.3% prior year)
- **Adjusted Gross Margin:** 45.9% (vs 50.7% prior year)
- **Adjusted EBITDA Loss:** $11.9M (vs $5.5M prior year)
- **EPS:** $(0.73) loss (missed $(0.46) estimate)

## Segment Performance

- **Simoa:** $23M (36% organic revenue decline)
- **Spatial:** $17.2M (9% YoY decline)
- **Diagnostics:** $2.4M in Q3

## LucentAD Alzheimer's Diagnostics

- Received positive pricing recommendation to crosswalk LucentAD test at **$897**
- Final approval decision expected later in quarter
- Clinical utility studies show five-marker algorithmic test outperforms single-marker tests
- Expect "a lot more traction in 2026 versus 2025"

## Business Model

- **80% recurring revenue** through consumables and reagents
- 7 consecutive quarters of double-digit growth
- FDA Breakthrough designation for LucentAD

## 2025 Guidance

- Revenue: $130-135M
- Pro forma (with Akoya): $165-170M
- On track for $85M annualized synergies
- Cash flow break-even expected 2026
